Correlation Between GP Act and Tscan Therapeutics
Can any of the company-specific risk be diversified away by investing in both GP Act and Tscan Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining GP Act and Tscan Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between GP Act III Acquisition and Tscan Therapeutics, you can compare the effects of market volatilities on GP Act and Tscan Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in GP Act with a short position of Tscan Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of GP Act and Tscan Therapeutics.
Diversification Opportunities for GP Act and Tscan Therapeutics
-0.59 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between GPAT and Tscan is -0.59. Overlapping area represents the amount of risk that can be diversified away by holding GP Act III Acquisition and Tscan Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Tscan Therapeutics and GP Act is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on GP Act III Acquisition are associated (or correlated) with Tscan Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Tscan Therapeutics has no effect on the direction of GP Act i.e., GP Act and Tscan Therapeutics go up and down completely randomly.
Pair Corralation between GP Act and Tscan Therapeutics
Given the investment horizon of 90 days GP Act III Acquisition is expected to generate 0.02 times more return on investment than Tscan Therapeutics. However, GP Act III Acquisition is 53.6 times less risky than Tscan Therapeutics. It trades about 0.36 of its potential returns per unit of risk. Tscan Therapeutics is currently generating about -0.09 per unit of risk. If you would invest 1,007 in GP Act III Acquisition on September 5, 2024 and sell it today you would earn a total of 7.00 from holding GP Act III Acquisition or generate 0.7% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 95.45% |
| Values | Daily Returns |
GP Act III Acquisition vs. Tscan Therapeutics
Performance |
| Timeline |
| GP Act III |
| Tscan Therapeutics |
GP Act and Tscan Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with GP Act and Tscan Therapeutics
The main advantage of trading using opposite GP Act and Tscan Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if GP Act position performs unexpectedly, Tscan Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tscan Therapeutics will offset losses from the drop in Tscan Therapeutics' long position.| GP Act vs. Tscan Therapeutics | GP Act vs. CECO Environmental Corp | GP Act vs. Spyre Therapeutics | GP Act vs. Kaiser Aluminum |
| Tscan Therapeutics vs. Apellis Pharmaceuticals | Tscan Therapeutics vs. Iteos Therapeutics | Tscan Therapeutics vs. Day One Biopharmaceuticals | Tscan Therapeutics vs. Acumen Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Complementary Tools
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |